BrainsWay Takes Minority Stake in Chicago-Based Mental Health Provider Hopemark Health
Event summary
- BrainsWay invests $1.5M initially in Hopemark Health, with potential for an additional $1.5M in milestone-based investments.
- The deal secures a minority stake in Hopemark, a Chicago-area mental health clinic management services organization.
- Hopemark specializes in outpatient psychiatric care, including ketamine-based therapies.
- BrainsWay aims to expand access to its Deep TMS technology through this strategic partnership.
- The investment includes a redemption mechanism for the shares.
The big picture
BrainsWay’s investment in Hopemark Health aligns with its strategy to partner with clinical platforms to expand access to advanced mental health treatments. This move comes as the neurostimulation market sees increased demand for non-invasive solutions, particularly for conditions like depression and OCD. The deal underscores BrainsWay’s focus on scaling its Deep TMS technology through strategic equity investments, rather than organic growth alone.
What we're watching
- Integration Strategy
- How BrainsWay will leverage Hopemark’s clinical platform to scale its Deep TMS technology.
- Milestone Performance
- Whether Hopemark meets the milestones required for the additional $1.5M investment.
- Competitive Positioning
- The pace at which BrainsWay can differentiate itself in the growing interventional psychiatry market.
Related topics